According to a press release published by Eli Lilly, GIP is a hormone that may complement the effects of GLP-1 receptor agonists
[39] These findings support a potential clinical role for oral orforglipron as a step-down or maintenance strategy after injectable GLP-1 or dual GIP/GLP-1 receptor agonist therapy, although long-term implementation depends on labeling, access, tolerability, and comparative durability
J.HallahanD
In 2024, researchers at the University of Arizona tested five different plant-based fibres for their effect on body weight and fat
However, no clinical trials have specifically evaluated the safety or efficacy of concurrent creatine and tirzepatide use
Creating a holistic exercise regimen that works with your schedule, incorporates your interests, is dynamic enough to prevent burnout, and sets reasonable goals